RA Capital Management’s NovoCure NVCR Stock Holding History

RA Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-259,099	Closed	-$17.4M	–	61
2020 Q1	$17.4M	Buy	+259,099	New	+$20.5M	0.55%	37

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

RA Capital Management's NVCR Position: Q2 2020 in Review

RA Capital Management sold out of NovoCure (NVCR) in Q2 2020, closing a stake of 259,099 shares — an estimated $17.4M sold.

RA Capital Management first reported a position in NVCR in Q1 2020 and held it in 1 quarter. The position peaked at $17.4M in Q1 2020. 264 funds tracked by Wall St. Rank hold NVCR as of Q2 2020.

RA Capital Management reported no remaining NovoCure position as of Q2 2020 after selling out during the quarter.
RA Capital Management sold 259,099 NovoCure shares in Q2 2020, an estimated $17.4M.
RA Capital Management first reported a position in NovoCure in Q1 2020 and held it in 1 quarter.
RA Capital Management's NovoCure position peaked at $17.4M in Q1 2020.
264 funds tracked by Wall St. Rank held NovoCure as of Q2 2020.

Based on RA Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.